AppLovin stock price target lowered to $664 by BTIG on mixed feedback

Connect Biopharma has received a Buy rating from BTIG, highlighting the company's promising potential in the respiratory drug market. This endorsement is significant as it suggests confidence in the company's innovative approaches and could attract more investors, boosting its stock performance. The focus on respiratory treatments is particularly timely given the ongoing global health challenges, making this development noteworthy for both the company and its stakeholders.

Arvinas has received a boost in its stock price target, now set at $14, up from $10, thanks to a positive assessment from BTIG regarding the potential of its KRASG12D degrader. This increase reflects growing confidence in the company's innovative approach to cancer treatment, which could significantly impact the market and provide new hope for patients. Investors are likely to view this as a strong signal of Arvinas' future prospects.

Flutter Entertainment's stock price target has been lowered to $321 by BTIG, reflecting concerns about the company's future performance. This adjustment is significant as it may influence investor confidence and market perception, potentially impacting Flutter's stock value in the coming months.

BTIG has raised its stock price target for Boot Barn from $218 to $226, reflecting confidence in the company's growth and performance. This adjustment indicates that analysts believe Boot Barn is on a positive trajectory, which could attract more investors and boost market interest in the brand.

Recent developments in the credit market are raising alarms for Wall Street, suggesting potential instability ahead. The metaphor of cockroaches sinking a ship highlights the concern that small issues can lead to larger problems in financial systems. This matters because it could signal a downturn in the economy, affecting investments and consumer confidence.

The Bloomberg Brief for October 31, 2025, provides a comprehensive overview of the latest developments in finance and markets. This video highlights key trends and insights that are shaping the economic landscape, making it essential for investors and analysts to stay informed. Understanding these updates can help individuals and businesses make better financial decisions.

LendInvest Secured Income II has reported an impressive £39 million in eligible loans for the third quarter of 2025. This significant figure highlights the growing confidence in the property finance market and showcases LendInvest's strong position in providing accessible funding solutions. As the demand for loans continues to rise, this achievement not only reflects the company's robust performance but also signals a positive trend for investors looking for reliable opportunities in the financial sector.

Connect Biopharma has received a Buy rating from BTIG, highlighting the company's promising potential in the respiratory drug market. This endorsement is significant as it suggests confidence in the company's innovative approaches and could attract more investors, boosting its stock performance. The focus on respiratory treatments is particularly timely given the ongoing global health challenges, making this development noteworthy for both the company and its stakeholders.

UBS has adjusted its price target for Zillow Group's stock from $95 to $92 while maintaining a 'Buy' rating. This change reflects UBS's analysis of the current market conditions and Zillow's performance. Investors should note that despite the lowered target, the 'Buy' rating suggests confidence in Zillow's long-term potential.

AppLovin's stock price target has been lowered to $664 by BTIG, reflecting mixed feedback from analysts. This adjustment highlights concerns about the company's performance and market perception, which could impact investor confidence and future growth prospects.